<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492698</url>
  </required_header>
  <id_info>
    <org_study_id>LW_clinical</org_study_id>
    <nct_id>NCT02492698</nct_id>
  </id_info>
  <brief_title>Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults</brief_title>
  <official_title>Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective was to evaluate the effect of the consumption of dual probiotic strains&#xD;
      containing Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L.&#xD;
      plantarum) KY1032 on weight loss, body adiposity and inflammatory markers including&#xD;
      lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in overweight subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled study was conducted on 120 subjects with age&#xD;
      between 20 and 65 years, nondiabetic (fasting blood glucose &lt;126 mg/dL and 2-hour blood&#xD;
      glucose &lt;200 mg/dL), and overweight (25 kg/m2 ≤ body mass index (BMI) &lt; 30 kg/m2). Over a 12&#xD;
      week test period, the probiotic group consumed 2 g of powder twice a day containing L.&#xD;
      curvatus HY7601 and L. plantarum KY1032, while the placebo group consumed the same product&#xD;
      without probiotics for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat percentage by dual-energy x-ray absorptiometry (DEXA) at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>Fat percentage (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat mass by DEXA at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>Fat mass (g)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lean body mass by DEXA at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>Lean body mass (g)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat area by computed tomography (CT) at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>Fat area (cm2) at levels of 1st lumbar (L1) vertebra and 4th lumbar (L4) vertebra</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>Total Cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>HDL Cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>LDL Cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>Triglyceride (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High sensitivity C-reactive protein (hs-CRP) at baseline and 12-week follow-up</measure>
    <time_frame>12-week follow-up</time_frame>
    <description>hs-CRP (mg/dL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Probiotic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>consumed 2 g of powder of a dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, twice a day after breakfast and dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>consumed 2g of powder that did not contain any probiotics, twice a day after breakfast and dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic group</intervention_name>
    <description>The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.</description>
    <arm_group_label>Probiotic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 20 and 65 years&#xD;
&#xD;
          -  Nondiabetic (fasting blood glucose &lt;126 mg/dL and 2-hour blood glucose &lt;200 mg/dL)&#xD;
&#xD;
          -  Overweight (25 kg/m2 ≤ body mass index (BMI) &lt; 30 kg/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Constant consumption of any probiotics products within 1 month before screening&#xD;
&#xD;
          -  Unstable body weight (body weight change &gt; 1 kg within 3 months before screening)&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Cerebrovascular disease&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Dietary supplementation within 6 months before screening&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Medication affecting body weight, energy expenditure, glucose control or antibiotic&#xD;
             treatment within 3 months before screening&#xD;
&#xD;
          -  Acute or chronic infections&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Gastrointestinal disease&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Medication or alcohol abuse&#xD;
&#xD;
          -  Any other acute or chronic disease requiring treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Ho Lee, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Food and Nutrition, College of Human Ecology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, South Korea</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>July 5, 2015</last_update_submitted>
  <last_update_submitted_qc>July 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Lp-PLA2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

